Recursion Pharmaceuticals
clinical target data from cohort analysis of phase prima trial for platinum sensitive ovarian cancer patients clinical benefit inhibitors is limited in negative proficient | Recursion Pharmaceuticals
Deck Type
Deck date
January 2023
Slide
68 of 143
Related slides by other companies
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io